Stryker invests about $400 million in CMR Surgical and will sell the Versius robot in the US
Image: Steve Bell Surgical Robotics / YouTube · video-thumbnail
Stryker and CMR Surgical announced an alliance on 12 October 2026: a preferred equity investment of about $400 million and exclusive U.S. sales rights for Versius.
Stryker and CMR Surgical announced a strategic alliance on 12 October 2026. Stryker will make a preferred equity investment of about $400 million, or £300 million, in the Cambridge, England, maker of the Versius soft-tissue surgical robot.
Under the agreement, Stryker becomes the exclusive U.S. sales agent for the Versius portfolio, while CMR keeps development and sales outside the United States. Stryker also receives an exclusive option to acquire the rest of CMR's equity at a later date. The deal is subject to regulatory approvals and customary closing conditions.
The terms of the sales agency, the option price and the closing date were not disclosed. Stryker already leads in orthopaedic robotics with Mako; Versius gives it a way into soft-tissue surgery, the field Intuitive's da Vinci has dominated for two decades.
Sources
- Stryker Primary source
- Bioxconomy
